Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EGFRvIII Peptide

A synthetic peptide sequence derived from the tumor specific mutant variant of epidermal growth factor receptor EGFRvIII originally found in… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND: EGFRvIII, a constitutively active tumorigenic EGFR deletion mutation, is linked to poor long-term survival. The… Expand
2014
2014
The tumor-specific epidermal growth factor receptor variant III mutation (EGFRvIII) is widely expressed in glioblastoma and thus… Expand
2013
2013
Glioblastoma, the most common primary malignant brain tumor, is among the most difficult cancers to treat. Despite the aggressive… Expand
2012
2012
Three different synthetic strategies were tested to synthesize EGFRvIII peptide (1), which is a functional variant of the… Expand
2006
2006
2529 Background: Despite multimodality approaches, survival with GBM is dismal. Induction of immune responses to suppress the… Expand
Highly Cited
2005
Highly Cited
2005
SummaryThe type III variant of the epidermal growth factor receptor (EGFRvIII) mutation is present in 20–25% of patients with… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2004
2004
EGFRvIII is the type III deletion mutant form of the epidermal growth factor receptor (EGFR) with transforming activity. This… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5